Birchview Capital’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Birchview Capital’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-8,000	Closed	-$602K	–	62
2022 Q2	$602K	Hold	8,000	–	–	0.44%	34
2022 Q1	$215K	Hold	8,000	–	–	0.15%	55
2021 Q4	$382K	Hold	8,000	–	–	0.25%	49
2021 Q3	$531K	Hold	8,000	–	–	0.36%	41
2021 Q2	$624K	Buy	+8,000	New	+$591K	0.37%	39

Birchview Capital's TPTX Position: Q3 2022 in Review

Birchview Capital sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 8,000 shares — an estimated $602K sold.

Birchview Capital first reported a position in TPTX in Q2 2021 and held it in 5 quarters. The position peaked at $624K in Q2 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Birchview Capital reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Birchview Capital sold 8,000 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $602K.
Birchview Capital first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Birchview Capital's Turning Point Therapeutics, Inc. Common Stock position peaked at $624K in Q2 2021.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Birchview Capital's 13F filing for Q3 2022, filed 7 Nov 2022.